BACKGROUND: Selecting patients for phase I trials in order to investigate cytotoxic agents is challenging, since there is no clear and reliable guidance to estimate life expectancy among these patients. We retrospectively assessed prognostic factors in cancer patients screened for Phase1 trials between October 1997 and October 2002. METHODS: 148 consecutive patients, screened for inclusion in phase I trials investigating cytotoxic agents, were included in the present study. 70 out of them actually received phase I trial regimens. Univariate and multivariate analysis were undertaken to determine the prognostic factors for overall survival (OS) from the date of screening. RESULTS: The median OS of the 148 patients was 5.7 months. Ninety-two percent of them had PS<or=1. The Cox model identified serum albumin<38 g/l [HR 2.51 (1.51-4.18), p=0.0001] and lymphocyte count<700/mm3 [HR 2.27 (1.13-4.62), p=0.024] as independent prognostic for overall survival. All patients presenting both prognostic factors died within 90 days. CONCLUSIONS: We propose a simple model, easily obtained at the bedside, which can discriminate patients who are likely to be alive at 3 months and thus could be included in a phase 1 anti-cancer trial. This model now needs to be validated on an independent cohort.
BACKGROUND: Selecting patients for phase I trials in order to investigate cytotoxic agents is challenging, since there is no clear and reliable guidance to estimate life expectancy among these patients. We retrospectively assessed prognostic factors in cancerpatients screened for Phase1 trials between October 1997 and October 2002. METHODS: 148 consecutive patients, screened for inclusion in phase I trials investigating cytotoxic agents, were included in the present study. 70 out of them actually received phase I trial regimens. Univariate and multivariate analysis were undertaken to determine the prognostic factors for overall survival (OS) from the date of screening. RESULTS: The median OS of the 148 patients was 5.7 months. Ninety-two percent of them had PS<or=1. The Cox model identified serum albumin<38 g/l [HR 2.51 (1.51-4.18), p=0.0001] and lymphocyte count<700/mm3 [HR 2.27 (1.13-4.62), p=0.024] as independent prognostic for overall survival. All patients presenting both prognostic factors died within 90 days. CONCLUSIONS: We propose a simple model, easily obtained at the bedside, which can discriminate patients who are likely to be alive at 3 months and thus could be included in a phase 1 anti-cancer trial. This model now needs to be validated on an independent cohort.
Authors: Pascal Seve; Isabelle Ray-Coquard; Veronique Trillet-Lenoir; Michael Sawyer; John Hanson; Christiane Broussolle; Sylvie Negrier; Charles Dumontet; John R Mackey Journal: Cancer Date: 2006-12-01 Impact factor: 6.860
Authors: Nicolas Penel; Nicolas Isambert; Pierre Leblond; Charles Ferte; Alain Duhamel; Jacques Bonneterre Journal: Invest New Drugs Date: 2009-01-10 Impact factor: 3.850
Authors: Nicolas Penel; Pierre Leblond; Amélie Lansiaux; Stéphanie Clisant; Eric Dansin; Antoine Adenis; Jacques Bonneterre Journal: Invest New Drugs Date: 2009-09-16 Impact factor: 3.850
Authors: Audrey E Kam; Gopichand Pendurti; Umang H Shah; Mohammad H Ghalib; Imran Chaudhary; Jennifer Chuy; Lakshmi Rajdev; Andreas Kaubisch; Santiago Aparo; Ioannis Mantzaris; Sanjay Goel Journal: Invest New Drugs Date: 2018-10-12 Impact factor: 3.850
Authors: Winson Y Cheung; Lindsay A Renfro; David Kerr; Aimery de Gramont; Leonard B Saltz; Axel Grothey; Steven R Alberts; Thierry Andre; Katherine A Guthrie; Roberto Labianca; Guido Francini; Jean-Francois Seitz; Chris O'Callaghan; Chris Twelves; Eric Van Cutsem; Daniel G Haller; Greg Yothers; Daniel J Sargent Journal: J Clin Oncol Date: 2016-02-08 Impact factor: 44.544
Authors: N Penel; S Clisant; E Dansin; C Desauw; M Dégardin; L Mortier; M Vanhuyse; F Bonodeau; C Fournier; J-L Cazin; A Adenis Journal: Br J Cancer Date: 2010-03-30 Impact factor: 7.640
Authors: Nicolas Penel; Antoine Hollebecque; Carlos Maynou; Jérôme Dewaele; Marie Jasserand; Régis Beuscart; Marie-Hélène Vieillard Journal: Support Care Cancer Date: 2008-05-14 Impact factor: 3.603
Authors: Nicolas Penel; Sylvie Negrier; Isabelle Ray-Coquard; Charles Ferte; Patrick Devos; Antoine Hollebecque; Michael B Sawyer; Antoine Adenis; Pascal Seve Journal: PLoS One Date: 2009-08-03 Impact factor: 3.240